Program
icg318
A development code. Also written as “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion”, “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T” and “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T”.
Its studies are mostly in Lupus Nephritis · Myositis · Inflammatory Bowel Diseases, led by iCell Gene Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| iCell Gene Therapeutics | 33 open or running | phase 2since Oct 17, 2025 | Oct 17, 2025 | Dec 31, 2027phase 1 · NCT07715136 |
Also a collaborator on its studies: icar-bio-therapeutics-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 17, 2025First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT07328581 · 20 planned · United States
- Apr 8, 2026Phase 2 study in Inflammatory Bowel DiseasesNCT07544160 · 18 planned · China
- Jul 6, 2026Phase 1 study in MyositisNCT07715136 · 10 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 1 study in MyositisNCT07715136
- Apr 7, 2028Primary completion: phase 2 study in Inflammatory Bowel DiseasesNCT07544160
- Dec 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07328581
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07715136Myositis · China | 1 | Recruiting | Dec 31, 2027 | 10 |
| NCT07544160Inflammatory Bowel Diseases · China | 2 | Not yet recruiting | Apr 7, 2028 | 18 |
| NCT07328581Lupus Erythematosus, Systemic · United States | 2 | Recruiting | Dec 2028 | 20 |
How it is read
Names in the registry
- “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion”, 1 entry
- “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T”, 1 entry
- “ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T”, 1 entry
Codes read as this program: ICG318.
Conditions, from the studies’ own filings
- Lupus Nephritis, 1 study
- Myositis, 1 study
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.